2026 年美国皮肤病学会年会：高德美发布最新临床证据，展现全面、科学的多元化皮肤需求解决方案

·在皮肤治疗产品组合中，高德美将展示奈莫利珠单抗在不同患者群体中治疗中重度特应性皮炎的疗效和安全性数据，包括儿科患者的最新突破性数据，并分享关于AKLIEF^®（曲法罗汀乳膏）的4篇壁报¹–⁸

·与皮肤护理相关的展示将探讨人工智能如何识别敏感性皮肤的高风险因素，以及丝塔芙^®在不同皮肤类型中的应用⁹

·来自高德美注射美学产品组合的数据还将展示其透明质酸注射产品瑞蓝^®以及新型液态A型肉毒毒素*如何满足面部及上胸部的美学需求¹⁰–¹⁴

·共计22篇展示将强化高德美在皮肤治疗、注射美学和皮肤护理领域满足患者多样化需求的广泛且综合的产品组合价值

致力于成为全球领先的专业皮肤学公司高德美将在2026年美国皮肤病学会（AAD）年会上展示其广泛产品组合中的最新创新成果，该大会将于3月27日至31日在美国科罗拉多州丹佛举行。共计将发布22篇摘要，包括最新突破性数据和三场口头报告，涵盖皮肤治疗、注射美学和皮肤护理领域。

“高德美正朝着成为皮肤学领域领军者的目标稳步迈进，致力于在该领域树立科学研究的卓越标杆。我们在AAD年会上发布的各类研究数据，充分体现了我们在全业务线践行这一目标的承诺。患者理应获得满足其多元化、不断变化需求的精细、有效的解决方案，而我们的科研创新正是为实现这一目标。”

BALDO SCASSELLATI SFORZOLINI, 医学博士，高德美全球研发与企业发展负责人

皮肤治疗：特应性皮炎与痤疮领域的最新研究进展

Four presentations on Nemluvio (nemolizumab), the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31, will explore

高德美将展示4篇关于奈莫利珠单抗在不同患者群体中治疗中重度特应性皮炎的疗效和安全性¹–⁴^,¹⁵–¹⁷的报告，该药物是首个获得批准的特异性靶向并抑制IL-31信号传导的单克隆抗体。

其中包括一篇关于奈莫利珠单抗在2至11岁儿童患者中的药代动力学、安全性和疗效¹的突破性报告，报告将于3月28日（周六）MDT时间10:24–10:36 / CET时间17:24–17:36在Bellco Theatre 3举行。

此外，一项基于 ARCADIA 长期扩展试验的后期数据展示，评估奈莫利珠单抗在长达 104 周的时间内对瘙痒症状与皮肤应答的长期维持效果²。该展示将于MDT 3 月 28 日周六 14:10-14:15（CET 21:10-21:15）在 C 大厅壁报中心 2 号厅举行。

其余两项壁报将分别呈现奈莫利珠单抗在青少年人群中长达2年的长期疗效与安全性数据，包含治疗16周时皮肤部分应答、微应答的人群接受104周治疗的疗效与安全性结果³,⁴。

MDT 3 月 29 日周日上午 10:30-11:15（CET当日下午 6:30-7:15），高德美将在 1 号报告厅举办产品专题研讨会，深入解读神经免疫相互作用在特应性皮炎与结节性痒疹发病中的核心作用，重点聚焦靶向 IL-31 的治疗方案如何改善患者临床结局。

同时，高德美还将发布关于AKLIEF^®（曲法罗汀乳膏）的4篇电子壁报，展示其四代维A酸类药物数十年的创新研发历程，其中重点介绍第四代曲法罗汀在痤疮治疗与皮肤健康管理中的作用，及其分子设计研发逻辑 ⁷,⁸。真实世界研究数据将进一步评估个性化治疗方案下，该药物对痤疮治疗结局与皮肤质量的改善效果，同时验证其用于印度患者面部与躯干痤疮的疗效与安全性 ⁵,⁶。

日常护肤：九项研究覆盖敏感性皮肤、痤疮、易患湿疹皮肤与熟龄肌

本次大会将发布两场口头报告，其中一场探讨如何通过人工智能识别敏感性皮肤的高风险因素（MDT 3 月 28 日周六下午 1:05-1:10 / CET当日晚 8:05-8:10，C 大厅壁报中心 2 号厅），另一场则分享针对皮肤科医师开展的异维 A 酸治疗后痤疮管理相关调研结果（MDT 3 月 29 日周日下午 3:10-3:15 / CET当日晚 11:10-11:15，C 大厅壁报中心 1 号厅）⁹,¹⁸

5篇电子壁报将深入研究高德美丝塔芙^®全系列产品在不同肤质中的应用特性，包括：丝塔芙^®Restoraderm湿疹舒缓保湿乳与Restoraderm湿疹快速舒缓霜针对易患湿疹皮肤患者的瘙痒缓解起效时间，丝塔芙^®产品在熟龄老化肌肤中的应用效果、有色润肤产品与不同防晒指数产品在多种肤色中的搭配应用，以及丝塔芙^®净润温和洁面乳产品的温和性验证 ¹⁹⁻²¹

在本届 AAD 年会召开前，高德美将与其全球敏感性皮肤护理专家委员会（Global Sensitive Skincare Faculty, 简称 GSSF）举办 2026 年丝塔芙^®创新论坛。届时，全球各地的皮肤科专业医护人员将齐聚一堂，分享以生物机理为核心的创新护肤方案（包括AM/PM 精华 、Skin Activator Hydrating & Firming 系列），如何通过两大核心生物学驱动因素改善皮肤老化，即氧化应激与细胞衰老，提升皮肤健康水平。这些研究成果将共同支持皮肤长效健康与强韧的整体愿景。

注射美学：探索不同治疗方案满足面部与身体多部位美学需求

五篇电子壁报将展示高德美注射美学产品组合的最新研发进展，核心数据包括：多功能瑞蓝^®透明质酸系列产品的相关研究，涵盖瑞蓝·丽瑅^®·丽多™用于下巴部位填充塑形、瑞蓝 ^®·Shaype™ 用于下颌线轮廓提升、瑞蓝·丰采^® 用于太阳穴凹陷矫正，以及瑞蓝·智臻^® 用于上胸部皱纹抚平的相关电子壁报 ¹⁰⁻¹³。还有高德美采用 PEARL™专利技术生产的即用型液态神经调节剂新型液态 A 型肉毒毒素*，用于不同年龄段求美者中重度眉间纹与鱼尾纹治疗的结局研究 ¹⁴。

注意：上述内容可能引述不同产品在其他国家或地区的使用和探索实践，包括某些尚未在中国大陆地区上市的产品或适应症，请注意加以区分，相关内容不构成诊疗推荐或医疗建议。高德美提醒医疗卫生专业人士在实际诊疗中，应基于求美者或患者的实际情况，并遵照国家药监局核准的相关产品说明书，做出专业的治疗决策。

关于高德美

高德美（瑞士证券交易所：股票代码为“GALD”）致力于成为专注皮肤学领域的全球领导者，业务遍及约90个国家和地区。我们提供创新、以科学为基础的优质旗舰品牌和服务组合，横跨注射美学、日常护肤和皮肤治疗这三个快速增长的皮肤学细分市场。自1981年成立以来，我们一直热忱专注于人体最大的器官——皮肤，与专业医务工作者合作，以卓越成果满足求美者、消费者和患者的个性化需求。肌肤塑造了我们的人生故事，由此，我们致力于不断推进“每一个进步为每一寸肌肤”。更多信息请访问：www.galderma.com

参考资料

1.Eichenfield LF, et al. Pharmacokinetics, safety, and efficacy of nemolizumab in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis. Abstract #79657. Late-breaking presentation at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

2.Thaçi D, et al. Long-term (up to 104 weeks) maintenance of itch and skin responses with nemolizumab treatment in patients with moderate-to-severe atopic dermatitis – post hoc analyses from the ARCADIA long-term extension (LTE) trial. Abstract #76707. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

3.Reich A, et al. Long-term efficacy and safety of nemolizumab in adolescents with moderate-to-severe atopic dermatitis: Post hoc analyses from ARCADIA LTE two-year cut-off. Abstract #76688. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

4.Silverberg JI, et al. Continuous response with nemolizumab – efficacy and safety up to 104 weeks in patients with moderate-to-severe atopic dermatitis with partial and minimal response (non-response) in skin at 16 weeks: post hoc analyses from ARCADIA LTE. Abstract #76623. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

5.Chandrashekar BS, et al. A 12-week real-world evaluation of safety and efficacy of trifarotene treatment for facial and truncal acne in Indian subjects. Abstract #75617. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

6.Dreno B, et al. Real-world evidence for a holistic regimen with trifarotene in acne and acne sequelae: Improving acne treatment outcomes and skin quality through personalized regimens. Abstract #73768. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

7.Gold LS, et al. From tretinoin to trifarotene: Fifty years of innovation in acne and skin health. Abstract #73796. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

8.Li MK, et al. The fourth-generation retinoid: Rational molecular design of trifarotene, selectivity, efficacy, and clinical outcomes. Abstract #73785. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

9.Farah M, et al. Identifying high-risk factors for sensitive skin through artificial intelligence: A cross-sectional analysis. Abstract #76215. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

10.Ablon G, et al. A randomized, comparator-controlled trial to evaluate a hyaluronic acid filler for augmentation of the chin region. Abstract #73111. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

11.Fabi S, et al. A randomized, evaluator-blinded, multicenter study to assess effectiveness and safety of a hyaluronic acid skin quality injectable for correction of wrinkles in the décolletage area. Abstract #72945. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

12.George R, et al. Long-term effectiveness and safety of a high G’ hyaluronic acid injectable as a treatment for restoring and enhancing the jawline. Abstract #72944. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

13.Siperstein R, et al. Correction of temple hollowing using a hyaluronic acid filler: Safety and effectiveness results from a randomized controlled investigation. Abstract #73119. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

14.Ablon G, et al. The influence of age on relabotulinumtoxinA outcomes in moderate-to-severe glabellar and lateral canthal lines: post-hoc analysis of three phase 3 double-blind, placebo-controlled trials. Abstract #74752. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

15.Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173–182. doi:10.1016/j.jaci.2019.08.013.

16.Nemluvio^® U.S. Prescribing Information. Available online. Accessed March 2026.

17.Nemluvio^® European Medicines Agency. Summary of Product Characteristics. Available online. Accessed March 2026.

18.Zarabian N, et al. Post-isotretinoin acne management: A survey of dermatology practitioners. Abstract #76347. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

19.Nguyen TQ, et al. Improvement in time to itch relief after use of both a lotion and cream for eczema patients. Abstract #76198. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

20.Nguyen TQ, et al. Blendability of a tinted moisturizer with SPF across many skin tones. Abstract #72440. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

21.Garimella S, et al. Assessing the mildness of cleansers using the corneosurfametery method. Abstract #76365. Poster presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27–31, 2026; United States.

免责声明：市场有风险，选择需谨慎！此文仅供参考，不作买卖依据。